News Beyond Air, Inc.

Equities

XAIR

US08862L1035

Market Closed - Nasdaq Other stock markets 03:59:46 2024-06-04 pm EDT			5-day change	1st Jan Change
1.2 ^USD	+2.56%		+8.60%	-38.78%

Apr. 30	Truist Lowers Price Target on Beyond Air to $8 From $10, Keeps Buy Rating	MT
Feb. 12	Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)	Jun. 03	AQ
Beyond Air : Corporate Presentation	May. 31	PU
Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast	May. 23	AQ
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting	May. 01	AQ
Truist Lowers Price Target on Beyond Air to $8 From $10, Keeps Buy Rating	Apr. 30	MT
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants	Mar. 20	AQ
Beyond Air : Corporate Presentation	Mar. 13	PU
Beyond Air, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Beyond Air, Inc. Provides Revenue Guidance for the Fiscal Year 2025	Feb. 12	CI
Transcript : Beyond Air, Inc., Q3 2024 Earnings Call, Feb 12, 2024	Feb. 12
Earnings Flash (XAIR) BEYOND AIR Posts Q3 Revenue $391,000, vs. Street Est of $0.45M	Feb. 12	MT
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024	Feb. 12	AQ
North American Morning Briefing : Stock Futures Steady as Traders Await CPI Data	Feb. 12	DJ
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast	Jan. 18	AQ
Beyond Air Affiliate Says First Group Cleared in Phase 1 UNO Study in Solid Tumors; Shares Rise	Dec. 27	MT
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors	Dec. 27	AQ
Thinking about buying stock in Polished.Com, Mereo BioPharma, Fusion Pharmaceuticals, Luminar Technologies, or Beyond Air?	Dec. 20	PR
Beyond Air Insider Bought Shares Worth $1,962,000, According to a Recent SEC Filing	Dec. 19	MT
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference	Nov. 15	AQ
Truist Cuts Beyond Air's Price Target to $10 From $14, Maintains Buy Rating	Nov. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Beyond Air, Inc.

Equities

XAIR

US08862L1035

Summary

Filters